OKYO Pharma to attend Jefferies London conference

Available on EDGAR 11/12/2026 - 07:00 AM EST Accepted by SEC EDGAR 11/12/2026 - 07:00 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Ltd (OKYO) said it will participate in the 2026 Jefferies Global Healthcare Conference in London, taking place November 16 to November 19, 2026. Its leadership team will be available for one-on-one investor meetings during the conference; interested investors are directed to contact their Jefferies representative. The company also said its lead candidate, urcosimod, recently had the first patients enrolled in the Phase 3 NEPTUNE trial for neuropathic corneal pain.

Key Figures

Conference dates: November 16 to November 19, 2026 Trial phase: Phase 3

2 metrics

Conference dates November 16 to November 19, 2026 2026 Jefferies Global Healthcare Conference in London

Trial phase Phase 3 NEPTUNE trial for neuropathic corneal pain; first patients enrolled

Key Terms

clinical-stage biopharmaceutical, neuropathic corneal pain (NCP), anterior segment eye diseases, urcosimod

4 terms

clinical-stage biopharmaceutical medical

"a clinical-stage biopharmaceutical company"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

neuropathic corneal pain (NCP) medical

"treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

urcosimod medical

"Lead candidate, urcosimod for neuropathic corneal pain"

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 12, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that it will participate at the 2026 Jefferies Global Healthcare Conference in London, United Kingdom taking place from November 16–19, 2026. The Leadership team will be available for one-on-one investor meetings throughout the conference. Investors interested in arranging a meeting should contact their Jefferies representative.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: November 12, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated November 12, 2026

4

Exhibit 99.1

OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London

London and New York, NY, November 12, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the 2026 Jefferies Global Healthcare Conference in London, United Kingdom taking place from November 16–19, 2026.

The Leadership team will be available for one-on-one investor meetings throughout the conference. Investors interested in arranging a meeting should contact their Jefferies representative.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. Lead candidate, urcosimod for neuropathic corneal pain (NCP), recently announced first patients enrolled in Phase 3 NEPTUNE trial. For more information, please visit www.okyopharma.com and follow us on LinkedIn.

Investor inquiries or meeting requests:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: ir@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 6.4 KB
• EX-99 GRAPHIC 7.4 KB